Relationship of the Serum CRP Level With the Efficacy of Metformin in the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis

Journal of Clinical Laboratory Analysis

Volumn 30, Issue 1, 2016, Pages 13-22

  Shi, Lei ^a   Tan, Guang Shan ^a   Zhang, Kun ^b  

^a Department of Pharmacy ^*  (China)

^b The Third People s Hospital of Liaocheng   (China)

Author keywords

C reactive protein; Meta analysis; Metformin; Type 2 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; METFORMIN;

ARTICLE; CHINA; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; INDIA; ISRAEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; ADULT; AGED; BLOOD; DATA BASE; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; ODDS RATIO; PUBLISHING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; C-REACTIVE PROTEIN; DATABASES AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; METFORMIN; MIDDLE AGED; ODDS RATIO; PUBLICATION BIAS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84954075286     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21803     Document Type: Article

References (67)

1. Lin Y, Sun Z. Current views on type 2 diabetes. J Endocrinol 2010;204:1-11.
2. Dudley B, Heiland B, Kohler-Rausch E, et al. Education and technology used to improve the quality of life for people with diabetes mellitus type II. J Multidiscip Healthc 2014;7:147-153.
3. Farvid MS, Qi L, Hu FB, et al. Phobic anxiety symptom scores and incidence of type 2 diabetes in US men and women. Brain Behav Immun 2014;36:176-182.
4. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36 Suppl 1:S67-74.
5. Wong G, Barlow CK, Weir JM, et al. Inclusion of plasma lipid species improves classification of individuals at risk of type 2 diabetes. PLoS One 2013;8:e76577.
6. Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm 2013;19:237-246.
7. Yamaguchi T, Sugimoto T. Bone metabolism and fracture risk in type 2 diabetes mellitus [Review]. Endocr J 2011;58:613-624.
8. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.
9. Brunetti A, Chiefari E, Foti D. Recent advances in the molecular genetics of type 2 diabetes mellitus. World J Diabetes 2014;5:128-140.
10. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus - Present and future perspectives. Nat Rev Endocrinol 2012;8:228-236.
11. Al Ali R, Mzayek F, Rastam S, et al. Forecasting future prevalence of type 2 diabetes mellitus in Syria. BMC Public Health, 2013;13:507.
12. Connelly J, Kirk A, Masthoff J, et al. The use of technology to promote physical activity in type 2 diabetes management: A systematic review. Diabet Med 2013;30:1420-1432.
13. Evans JM, Mackison D, Swanson V, et al. Self-monitoring among non-insulin treated patients with type 2 diabetes mellitus: Patients' behavioural responses to readings and associations with glycaemic control. Diabetes Res Clin Pract 2013;100:235-242.
14. Foster PD, Mamdani MM, Juurlink DN, et al. Trends in selection and timing of first-line pharmacotherapy in older patients with type 2 diabetes diagnosed between 1994 and 2006. Diabet Med 2013;30:1209-1213.
15. Fouqueray P, Pirags V, Inzucchi SE, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2013;36:565-568.
16. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655.
17. Kumar R, Chhatwal S, Arora S, et al. Antihyperglycemic, antihyperlipidemic, anti-inflammatory and adenosine deaminase-lowering effects of garlic in patients with type 2 diabetes mellitus with obesity. Diabetes Metab Syndr Obes 2013;6:49-56.
18. Forst T, Michelson G, Ratter F, et al. Addition of liraglutide in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med 2012;29:1115-1118.
19. Mantovani A, Garlanda C, Doni A, et al. Pentraxins in innate immunity: From C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008;28:1-13.
20. Molins B, Pena E, Vilahur G, et al. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol 2008;28:2239-2246.
21. Pfutzner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006;8:28-36.
22. Liu S, Ren J, Xia Q, et al. Preliminary case-control study to evaluate diagnostic values of C-reactive protein and erythrocyte sedimentation rate in differentiating active Crohn's disease from intestinal lymphoma, intestinal tuberculosis and Behcet's syndrome. Am J Med Sci 2013;346:467-472.
23. Latina JM, Estes NA, 3rd, Garlitski AC. The Relationship between obstructive sleep apnea and atrial fibrillation: A complex interplay. Pulm Med 2013;2013:621736.
24. Ong KL, Tso AW, Xu A, et al. Evaluation of the combined use of adiponectin and C-reactive protein levels as biomarkers for predicting the deterioration in glycaemia after a median of 5.4 years. Diabetologia 2011;54:2552-2560.
25. Zhu Y, Zhang Y, Ling W, et al. Fruit consumption is associated with lower carotid intima-media thickness and C-reactive protein levels in patients with type 2 diabetes mellitus. J Am Diet Assoc 2011;111:1536-1542.
26. Sindhu S, Singh HK, Salman MT, et al. Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients. J Pharmacol Pharmacother 2011;2:261-265.
27. Stocker DJ, Taylor AJ, Langley RW, et al. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007;153 445:e441-446.
28. Mao XM, Liu H, Tao XJ, et al. Independent anti-inflammatory effect of insulin in newly diagnosed type 2 diabetes. Diabetes Metab Res Rev 2009;25:435-441.
29. Farah R, Shurtz-Swirski R, Lapin O. Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment. Cardiovasc Diabetol 2008;7:20.
30. Wang L, Ning J. Effects of metformin on C-reactive protein and complement factor C3 in patients of obese type 2 diabetes mellitus. Shanxi Med J 2006;35:888-889.
31. Huang CZ, Qin CW, Wang Y. Effect of pioglitazone hydrochloride on CRP and IL-6 of patients with type 2 diabetes mellitus. J Pract Diagn Ther 2008;22:215-216.
32. Park JS, Cho MH, Nam JS, et al. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur J Endocrinol 2011;164:69-74.
33. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
34. Zintzaras E, Ioannidis JP. HEGESMA: Genome search meta-analysis and heterogeneity testing. Bioinformatics 2005;21:3672-3673.
35. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123-137.
36. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
37. Song F, Gilbody S. Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. BMJ 1998;316: 471.
38. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006;295:676-680.
39. Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract 2011;93:56-62.
40. Chen JF, Chen NQ, Yang HY. The effects of metformin on the serum levels of adiponectin, interleukin-18 and C-reactive protein in patients with type 2 diabetes mellitus. Chin J Diabetes 2008;16:617-618.
41. Fang M. Comparison of therapeutic effects of metformin and volglibose on insulin and inflammatory factor of patients with type 2 diabetes mellitus. Strait Pharmaceutical J 2012;24:100-102.
42. Gao L, Yu DM. Effect of rosiglitazone on urinary albumin excretion in patients with early diabetic nephropathy. Chin J Prevention Contr Chronic Dis 2007;15:126-128.
43. Kadoglou NP, Tsanikidis H, Kapelouzou A, et al. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism 2010;59:373-379.
44. Ke XY, Yuan HZ. Effect of metformin and rosiglitazone on serum adiponectin in early type 2 diabetic nephropathy. China J Mod Med 2012;22:93-95.
45. Lai ZF, Shen HY, Tan XD, et al. Effect of metformin and sulfonylurea on high sensitive C-reactive protein level in type 2 diabetic patients. Clin Focus 2007;22:1386-1388.
46. Li Y, Pang J, Li SL, et al. The relationship of insulin resistance and high sensitive C-reactive protein and the intervention effect of of insulin sensitizer in patients with obese type 2 diabetes mellitus. J Practical Med 2009;25:4158-4160.
47. Lin X, Huang Y. Effects of rosiglitazone on endothelium-dependent vasodilation in patients with Type 2 diabetes. Chin Mod Doctor 2013;51:56-58+61.
48. Tian XN, Zeng ZY, Chen DF, et al. Effect of insulin sensitizer on the serum C-reactive protein of patients with newly diagnosed type 2 diabetes mellitus. J Clin Int Med 2007;24:128-129.
49. Tong XZ, Liao W. Effect of Chinese medicinal of fortify the spleen and resolve phlegm on serumal CRP and IL-6 of patients with type 2 diabetes melllitus of syndrome of dampness-heat encumbering the spleen. Chin Arch Tradit Chin Med 2009;27:221-223.
50. Wang SJ. Influence of metformin on C-reactive protein in patients with type 2 diabetes mellitus. J Pract Med Technique 2005;12:2352-2353.
51. Wang SY, Shen TT. Observation of curative effect of rosiglitazone combined with metformin on type 2 diabetes mellitus. Mod J Integr Tradit Chin West Med 2012;21:1046-1047+1050.
52. Wei LG. Effect of pioglitazone on blood lipid and hs-CRP in patients with newly diagnosed type 2 diabetes mellitus. Guide China Med 2013;11:132-133.
53. Xie S. Intervention effect of metformin on type 2 diabetes mellitus and its chronic inflammation. Aerospace Med 2009;19:79-80.
54. Xu Q, Zhang FH, Xu AM, et al. Effect of metformin on the serum resistin and insulin-like growth factor-I in patients with obese type 2 diabetes mellitus. Chin J Clin 2013;7:5798-5801.
55. Xu XH, Wu JD, Shen Y, et al. Effect of rosiglitazone on adipose cell cytokine and insulin resistance in patients with newly diagnosed type 2 diabetes mellitus. J Pract Med 2008;24:3567-3568.
56. Yatagai T, Nakamura T, Nagasaka S, et al. Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. Diabetes Res Clin Pract 2004;63:19-26.
57. Yuan ML. Clinical observation of the combination of metformin and pioglitazone in treating obese patients with newly diagnosed type 2 diabetes mellitus. Chin J Med Guide 2012;14:433-434.
58. Zhang H. Effect of insulin sensitizer on the serum C-reactive protein of patients with newly diagnosed type 2 diabetes mellitus. Tianjin Pharmacy 2011;23:52-53.
59. Zhang Y, Yang HY, Tan ZM. Effect of the combination of pioglitazone and metformin on high sensitive C-reactive protein and d-dimer in patients with type 2 diabetes mellitus. Mod J Integrated Traditional Chin Western Med, 2013;22:723-724.
60. Zhang YF, Yang XH, Zheng YG. Effect of rosiglitazone and metformin on the serum apelin and visfatin level in patients with newly diagnosed type 2 diabetes mellitus. Shandong Med J 2010;50:68-69.
61. Zhou Q, Huang SP. The clinical study on treatment of patients with obese type 2 diabetes mellitus with berberine and metformin. J Pract Diabetol 2012;8:33-35.
62. Zhu HL, Mu XY, Hu JT. Effect of the combination of atorvastatin and metformin on C-reactive protein in patients with type 2 diabetic hyperlipemia. China Pract Med 2013;8:189-190.
63. Zhu ZL, Qiu XC, Zhu HP, et al. Application of acarbose combined with metformin in treatment of newly diagnosed type 2 diabetes patients. Heilongjiang Med J 2011;24:223-225.
64. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: New insights from an old molecule. QJM 2003;96:793-807.
65. Pradhan AD, Everett BM, Cook NR, et al. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: The LANCET randomized trial. JAMA 2009;302:1186-1194.
66. Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. Diabetes 2002;51:1157-1165.
67. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes 2003;52:1799-1805.